Federation des caisses Desjardins du Quebec’s Adaptimmune Therapeutics ADAP Stock Holding History

Federation des caisses Desjardins du Quebec’s Portfolio ADAP Stock Details ADAP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-53,186	Closed	-$6.91K	–	2884
2025 Q3	$6.91K	Hold	53,186	–	–	﹤0.01%	2373
2025 Q2	$12.8K	Hold	53,186	–	–	﹤0.01%	1948
2025 Q1	$10.5K	Buy	53,186 +52,431	+6,945%	+$27.1K	﹤0.01%	1945
2024 Q4	$407	Hold	755	–	–	﹤0.01%	2409
2024 Q3	$717	Sell	755 -30	-4%	-$34	﹤0.01%	2354
2024 Q2	$765	Hold	785	–	–	﹤0.01%	2216
2024 Q1	$1.24K	Hold	785	–	–	﹤0.01%	2174
2023 Q4	$623	Hold	785	–	–	﹤0.01%	2186
2023 Q3	$612	Buy	785 +30	+4%	+$25	﹤0.01%	2194
2023 Q2	$698	Buy	+755	New	+$900	﹤0.01%	2169

Other funds holding ADAP

JAIC

Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return

Empirical Finance Havertown, Pennsylvania $2.13B AUM 29.56% 1-Year Est. Return

Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Federation des caisses Desjardins du Quebec's ADAP Position: Q4 2025 in Review

Federation des caisses Desjardins du Quebec sold out of Adaptimmune Therapeutics (ADAP) in Q4 2025, closing a stake of 53,186 shares — an estimated $6.91K sold.

Federation des caisses Desjardins du Quebec first reported a position in ADAP in Q2 2023 and held it in 10 quarters. The position peaked at $12.8K in Q2 2025. 10 funds tracked by Wall St. Rank hold ADAP as of Q4 2025.

Federation des caisses Desjardins du Quebec reported no remaining Adaptimmune Therapeutics position as of Q4 2025 after selling out during the quarter.
Federation des caisses Desjardins du Quebec sold 53,186 Adaptimmune Therapeutics shares in Q4 2025, an estimated $6.91K.
Federation des caisses Desjardins du Quebec first reported a position in Adaptimmune Therapeutics in Q2 2023 and held it in 10 quarters.
Federation des caisses Desjardins du Quebec's Adaptimmune Therapeutics position peaked at $12.8K in Q2 2025.
10 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2025.

Based on Federation des caisses Desjardins du Quebec's 13F filing for Q4 2025, filed 12 Feb 2026.